Navigation Links
Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
Date:4/1/2008

tein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA.

About Monogram

Monogram is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the demand for our testing products, including our Trofile Assay, the potential use of our Trofile Assay for patient selection for the class of HIV drugs known as CCR5 antagonists, the size and timing of Progenics' clinical trials utilizing our products, the outlook for Progenics' investigational drug mentioned in this release and for our testing products, expected protection provided by patents, possible regulation of our products by the FDA. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for CCR5 antagonists or other HIV drugs; whether larger confirmatory clinical studies will confirm the results of initial studies;
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
2. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
3. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Calif. , May 1, 2015 The ... its 2015 health literacy award winners. The IHA Health ... that make an impact on the practice of educating ... health literacy. IHA gives awards in three categories: innovative ... bestowed its Health Literacy Hero award. In ...
(Date:5/1/2015)... May 1, 2015  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... for the third quarter fiscal year 2015 on ... a conference call that same day, Thursday, May ...
(Date:4/30/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a medical products ... results for the fourth quarter and fiscal year ended ... 2015 overview: , Revenues from continuing operations of ... last year,s comparable quarter, and $202.6 million for fiscal ... $0.50 for the fourth quarter, up 194% over last ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24
... Viveve, Inc. , a development stage women,s health company, ... (Conformite Europeenne) mark for the use of its Viveve ... vaginal introitus (opening), after childbirth, to improve female sexual ... "The CE mark is a key milestone in our ...
... SAN FRANCISCO, Jan. 6, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... the company,s chairman and chief executive officer, is scheduled to ... in San Francisco, CA on Thursday, January 13th at 11:30 ... To access the live audio webcast or the subsequent archived ...
Cached Medicine Technology:Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... Burnsville MN (PRWEB) May 03, 2015 ... in workplace safety solutions, announces its appearance at the ... Health Conference. Products that HealthPostures will exhibit at the ... Largest of the sit stand solutions is the 6100 ... push button height control, an adjustable keyboard tray, extended ...
(Date:5/2/2015)... May 02, 2015 ProText Kinetic 2 is ... in Final Cut Pro X. ProText Kinetic 2 features ... Final Cut Pro X . Easily create interactive ... Pixel Film Studios' ProText Kinetic 2. , Using ProText Kinetic ... staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
(Date:5/1/2015)... and Caicos Islands, BWI (PRWEB) May 02, 2015 ... new website! It is http://www.thevenetiangracebay.com , and ... and it incorporates the stunning white and attractive turquoise ... a study of Google, sixty seven percent of leisure ... The study showed that smartphones were used in the ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... Sept. 5 The Health Resources,and Services Administration ... and improve medical services at the nation,s health ... expansion of the,health center network, whose services now ... ever before," HRSA,Administrator Elizabeth M. Duke said. "In ...
... Arthrosurface, Inc.,( http://www.arthrosurface.com ), the developer of ... approval from the U.S.,FDA to begin its pivotal ... The FDA stated that "there are no outstanding ... initiation., Arthrosurface has been evaluating the safety ...
... Sept. 5 U.S. citizens can donate,money to ... Hurricane,Gustav, which is the worst storm to hit ... "Donations will be used for basic supplies that ... Wachtenheim, Director of the Cuban,Development Initiative at the ...
... say patients taking meds on Web site shouldn,t overreact or ... The U.S. Food and Drug Administration has started listing on ... the agency said Friday. , "If a drug appears ... to determine whether there is a safety problem that requires ...
... to physicians by pharmaceutical companies could actually be costing ... a study done by researchers at Wake Forest University ... looked at the prescribing habits of more than 70 ... months immediately before and after the closing of their ...
... 3 studies focus on brain and pancreatic tumors , , ... involving genetic mutations of two deadly cancers -- the ... to new treatments and even cures, researchers say. ... to date of any tumor type and provide a ...
Cached Medicine News:Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
AST (SGOT) R1 + R2. Automated analyzer test kits....
For the quantitative colorimetric determination of AST (SGOT) in serum....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: